Ipilimumab Clinical Trials
78 recruitingDrug
Phase 255Phase 130Phase 35Early Phase 12Not Applicable1Phase 41
Showing 1–20 of 78 trials
Recruiting
Phase 2
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)50 enrolled92 locationsNCT05904080
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled580 locationsNCT03866382
Recruiting
Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Recurrent Endometrial CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)81 enrolled137 locationsNCT05112601
Recruiting
Phase 1Phase 2
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more
NRG Oncology240 enrolled318 locationsNCT05327686
Recruiting
Phase 2
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Renal Cell CarcinomaBrain Metastases
M.D. Anderson Cancer Center20 enrolled1 locationNCT05048212
Recruiting
Phase 3
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Advanced Hepatocellular Carcinoma
NRG Oncology226 enrolled107 locationsNCT07166406
Recruiting
Phase 2
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting
Phase 1Phase 2
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled8 locationsNCT07227012
Recruiting
Phase 1Phase 2
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Advanced Solid Tumors
ModernaTX, Inc.361 enrolled28 locationsNCT05533697
Recruiting
Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Unresectable Pleural Mesothelioma
AstraZeneca825 enrolled178 locationsNCT06097728
Recruiting
Phase 2
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Melanoma Stage IVInoperable DiseaseMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute29 enrolled1 locationNCT04562129
Recruiting
Phase 2Phase 3
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma
Replimune Inc.280 enrolled33 locationsNCT06581406
Recruiting
Phase 2
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
MelanomaAdvanced MelanomaMelanoma Stage IV+1 more
H. Lee Moffitt Cancer Center and Research Institute90 enrolled1 locationNCT06295159
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb234 enrolled72 locationsNCT07293351
Recruiting
Phase 2
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Brown University25 enrolled1 locationNCT04933903
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled29 locationsNCT05536141
Recruiting
Phase 4
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
OncologyInfusion Reaction
Isala776 enrolled1 locationNCT06031233
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled45 locationsNCT07291076